• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    11/14/24 12:24:46 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COGT alert in real time by email
    SC 13G/A 1 cogta1_111424.htm KYNAM CAPITAL MANAGEMENT, LP cogta1_111424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Cogent Biosciences, Inc.
    (Name of Issuer)
    Common Stock, par value $0.001
    (Title of Class of Securities)
    19240Q201
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 19240Q201
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3660072
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    9,239,731
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    9,239,731
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    9,239,731
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.36%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 19240Q201
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management GP, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3678691
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    9,239,731
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    9,239,731
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    9,239,731
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.36%
    12
    TYPE OF REPORTING PERSON
    OO
    CUSIP No.: 19240Q201
           
    1
    NAME OF REPORTING PERSON
    Yue Tang
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    9,239,731
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    9,239,731
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    9,239,731
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.36%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 19240Q201
    ITEM 1(a). NAME OF ISSUER:
    Cogent Biosciences, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    275 Wyman St. 3rd Floor
    Waltham, MA USA
    02451
    ITEM 2(a). NAME OF PERSON FILING:
    Kynam Capital Management, LP
    Kynam Capital Management GP, LLC
    Yue Tang
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    221 Elm Road. Princeton, NJ 08540
    ITEM 2(c). CITIZENSHIP:
    Delaware
    Delaware
    U.S.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, par value $0.001
    ITEM 2(e). CUSIP NUMBER:
    19240Q201
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    9,239,731
    (b) Percent of class:
    8.36%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (ii) shared power to vote or to direct the vote:
    Kynam Capital Management, LP : 9,239,731

    Kynam Capital Management GP, LLC : 9,239,731

    Yue Tang : 9,239,731
    (iii) sole power to dispose or direct the disposition of:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (iv) shared power to dispose or to direct the disposition of:
    Kynam Capital Management, LP : 9,239,731

    Kynam Capital Management GP, LLC : 9,239,731

    Yue Tang : 9,239,731
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 19240Q201
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14 2024
    Kynam Capital Management, LP By: Kynam Capital Management GP, LLC, its General Partner
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    November 14 2024
    Kynam Capital Management GP, LLC
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    November 14 2024
    Yue Tang
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $COGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COGT

    DatePrice TargetRatingAnalyst
    11/10/2025$40.00Hold → Buy
    Stifel
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    10/16/2025$16.00Hold
    Stifel
    9/3/2025$30.00Strong Buy
    Raymond James
    3/7/2025$17.00Sector Outperform
    Scotiabank
    12/11/2024Buy → Hold
    Needham
    2/26/2024$14.00 → $8.00Outperform → Neutral
    Robert W. Baird
    2/8/2024$11.00Buy
    Citigroup
    More analyst ratings

    $COGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cogent Biosciences upgraded by Stifel with a new price target

    Stifel upgraded Cogent Biosciences from Hold to Buy and set a new price target of $40.00

    11/10/25 11:01:45 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences upgraded by Wedbush with a new price target

    Wedbush upgraded Cogent Biosciences from Neutral to Outperform and set a new price target of $38.00

    11/10/25 10:13:55 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Cogent Biosciences with a new price target

    Stifel initiated coverage of Cogent Biosciences with a rating of Hold and set a new price target of $16.00

    10/16/25 8:24:32 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

    WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 a.m. GMT (6:30 a.m. ET). A live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Cogent Biosciences, Inc.Cogent Biosciences is a biotechnology company focu

    11/14/25 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ferrante Karen Jean

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    10/3/25 4:16:22 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fairmount Funds Management Llc bought $24,999,993 worth of shares (2,777,777 units at $9.00) (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/14/25 4:30:37 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ferrante Karen Jean

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/2/25 4:15:43 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    SEC Filings

    View All

    SEC Form 8-K filed by Cogent Biosciences Inc.

    8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

    12/8/25 4:05:52 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

    11/18/25 4:09:49 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.

    SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/25 4:16:57 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $24,999,993 worth of shares (2,777,777 units at $9.00) (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/14/25 4:30:37 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Pinnow Cole bought $332,412 worth of shares (43,750 units at $7.60), increasing direct ownership by 2,085% to 45,848 units (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    1/15/25 7:00:04 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Leadership Updates

    Live Leadership Updates

    View All

    Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

    WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients

    5/23/24 5:05:00 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

    WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou

    11/28/22 4:15:00 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

    CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad

    5/3/21 7:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Financials

    Live finance-specific insights

    View All

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

    -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population -- -

    7/7/25 7:06:05 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 7:59:55 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 5:47:15 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 4:05:10 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care